Journal of Antimicrobial Chemotherapy (2002) 49, 851-855
© 2002 The British Society for Antimicrobial Chemotherapy
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10 000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000)
University of Iowa College of Medicine, Iowa City; the JONES Group/JMI Laboratories, North Liberty, IA; and Tuft’s University School of Medicine, Boston, MA, USA
Received 27 July 2001; returned 7 January 2002; revised 6 February 2002; accepted 13 February 2002.
BMS284756 is a novel des-F (6)-quinolone, which has a wide range of activity against many species of Gram-positive and -negative organisms. The potency of BMS284756 was compared with that of other quinolones, including ciprofloxacin, gatifloxacin and levofloxacin, and was tested against >10 000 bloodstream isolates from the year 2000 SENTRY antimicrobial surveillance programme. Twelve pathogens accounted for nearly all of the referred isolates and included Staphylococcus aureus, coagulase-negative staphylococci, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Serratia spp., Pseudomonas aeruginosa, Acinetobacter spp., Enterococcus spp., Streptococcus pneumoniae and ß-haemolytic or viridans group streptococci. Of the four quinolones tested, BMS284756 was the most active overall against Staphylococcus spp. (MIC50 
0.03 mg/L) and Streptococcus spp. (MIC50 0.06 mg/L). In contrast, BMS284756 was less potent than the other quinolones against the enteric Gram-negative bacilli (MIC50 0.03–1 mg/L). With a proposed breakpoint of 4 mg/L, BMS284756 may be a therapeutic alternative pending the results of clinical trials.
* Correspondence address. The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. Tel: +1-319-665-3370; Fax: +1-319-665-3371; E-mail: ronald-jones{at}jmilabs.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J. Christiansen, J. M. Bell, J. D. Turnidge, and R. N. Jones Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2049 - 2055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Gordon, P. R. Rhomberg, and R. N. Jones Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a Novel Desfluoroquinolone J. Clin. Microbiol., August 1, 2003; 41(8): 3967 - 3969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Credito, M. R. Jacobs, and P. C. Appelbaum Time-Kill Studies of the Antianaerobe Activity of Garenoxacin Compared with Those of Nine Other Agents Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1399 - 1402. [Abstract] [Full Text] [PDF]
|
|